These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 9816275)

  • 1. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
    Fleming RA; Capizzi RL; Muss HB; Smith S; Fernandes DJ; Homesley H; Loggie BW; Case L; Morris R; Russell GB; Richards F
    Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
    Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
    Chan TC; Markman M; Cleary S; Howell SB
    Cancer Res; 1986 Jun; 46(6):3168-72. PubMed ID: 3698032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
    Hageboutros A; Rogatko A; Newman EM; McAleer C; Brennan J; LaCreta FP; Hudes GR; Ozols RF; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1995; 35(3):205-12. PubMed ID: 7805178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
    Jodrell DI; Oster W; Kerr DJ; Canney PA; Yosef H; Steward WP; Kaye SB; Cassidy J
    Eur J Cancer; 1994; 30A(7):950-5. PubMed ID: 7946590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
    Ardalan B; Ucar A; Reddy R; Livingstone AS; Markoe A; Schwade J; Richman SP; Donofrio K
    Cancer; 1994 Oct; 74(7):1869-73. PubMed ID: 8082092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of continuous-infusion PALA and 5-FU.
    Ardalan B; Jamin D; Jayaram HN; Presant CA
    Cancer Treat Rep; 1984 Mar; 68(3):531-4. PubMed ID: 6231102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.
    Köhne CH; Harstrick A; Hiddemann W; Schöffski P; Wilke H; Bokemeyer C; Dörken B; Schmoll HJ
    Eur J Cancer; 1997 Oct; 33(11):1896-9. PubMed ID: 9470854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
    Seiter K; Kemeny N; Martin D; Schneider A; Williams L; Colofiore J; Sawyer R
    Cancer; 1993 Mar; 71(5):1875-81. PubMed ID: 8448752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
    O'Dwyer PJ; Paul AR; Walczak J; Weiner LM; Litwin S; Comis RL
    J Clin Oncol; 1990 Sep; 8(9):1497-503. PubMed ID: 2391557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
    Ardalan B; Singh G; Silberman H
    J Clin Oncol; 1988 Jun; 6(6):1053-8. PubMed ID: 3373260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
    Kemeny N; Conti JA; Seiter K; Niedzwiecki D; Botet J; Martin D; Costa P; Wiseberg J; McCulloch W
    J Clin Oncol; 1992 May; 10(5):747-52. PubMed ID: 1569447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of PALA on the pharmacokinetics of 5-fluorouracil.
    Nassim MA; Rouini MR; Cripps MC; Shirazi FH; Veerasinghan S; Molepo JM; Obrocea M; Redmond D; Bates S; Fry D; Stewart DJ; Goel R
    Oncol Rep; 1998; 5(1):217-21. PubMed ID: 9458325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
    O'Dwyer PJ; Hudes GR; Colofiore J; Walczak J; Hoffman J; LaCreta FP; Comis RL; Martin DS; Ozols RF
    J Natl Cancer Inst; 1991 Sep; 83(17):1235-40. PubMed ID: 1714507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of high dose 5-fluorouracil and high dose Leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
    Ardalan B; Stridhar K; Reddy R; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Livingstone A
    Int J Radiat Oncol Biol Phys; 1992; 22(3):511-4. PubMed ID: 1735689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
    Rosvold E; Schilder R; Walczak J; DiFino SM; Flynn PJ; Banerjee TK; Heim WJ; Engstrom PF; Ozols RF; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1992; 29(4):305-8. PubMed ID: 1537077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
    Erlichman C; Donehower RC; Speyer JL; Klecker R; Chabner BA
    J Natl Cancer Inst; 1982 Feb; 68(2):227-31. PubMed ID: 6950156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.
    Markman M; Chan TC; Cleary S; Howell SB
    Cancer Chemother Pharmacol; 1987; 19(1):80-3. PubMed ID: 3815730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.
    Hageboutros A; Hudes GR; Greene F; LaCreta FP; Brennan J; O'Dwyer PJ
    Invest New Drugs; 1997; 15(2):139-45. PubMed ID: 9220293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
    Ardalan B; Sridhar KS; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Fodor M; Livingstone A
    Cancer; 1991 Sep; 68(6):1242-6. PubMed ID: 1873776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.